Injectable chitosan hydrogels for localised cancer therapy

Ta, Hang T.; Dass, Crispin R.; Dunstan, Dave E.

doi:10.1016/j.jconrel.2007.11.018

Cited by 260 publications

(184 citation statements)

References 96 publications

Supporting

Mentioning

176

Contrasting

Unclassified

Order By: Relevance

“…However, the risk of recurrence stemming from residual cancer cells remains, and may be averted through administration of local radiotherapy or systemic chemotherapy. In systemic chemotherapy, the antitumor activity of anticancer drugs may be enhanced by changing the manner of drug administration, with particular focus on direct intratumoral injection (Goldberg et al, 2002;Ta et al, 2008;Rossi et al, 2003). Such targeted delivery would be expected to provide a high local concentration of the anticancer drug, reducing systemic drug levels and thereby decreasing the incidence of side-effects commonly observed with systemic therapy (Chvapil, 2005).…”

Section: Introductionmentioning

confidence: 99%

In vivo efficacy of paclitaxel-loaded injectable in situ-forming gel against subcutaneous tumor growth

Lee

Kim

Kang

et al. 2010

International Journal of Pharmaceutics

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

In vivo efficacy of paclitaxel-loaded injectable in situ-forming gel against subcutaneous tumor growth

Lee

Kim

Kang

et al. 2010

International Journal of Pharmaceutics

View full text Add to dashboard Cite

“…These compounds usually form hydrogel-drug complexes outside of the body and are then delivered into the body. [5][6][7][8][9] However, the formation of hydrogels frequently involves ultraviolet photopolymerization and various chemical cross-linking techniques, and there is a potential risk that toxic reagents may fail to be removed completely prior to hydrogel implantation. Furthermore, some hydrogels have high elasticity, which generally prevents their extrusion through a syringe needle.…”

Section: Introductionmentioning

confidence: 99%

“…5 The release was observed over a period of five days. As shown in Figure 7B, the RADA16 -PTX suspension could form a milky-white gel in phosphate-buffered saline, and the volume of hydrogel was obviously reduced over the release time.…”

mentioning

confidence: 99%

Controlled release of paclitaxel from a self-assembling peptide hydrogel formed in situ and antitumor study in vitro

Liu¹

2011

IJN

106

View full text Add to dashboard Cite

Background A nanoscale injectable in situ-forming hydrogel drug delivery system was developed in this study. The system was based on a self-assembling peptide RADA16 solution, which can spontaneously form a hydrogel rapidly under physiological conditions. We used the RADA16 hydrogel for the controlled release of paclitaxel (PTX), a hydrophobic antitumor drug. Methods The RADA16-PTX suspension was prepared simply by magnetic stirring, followed by atomic force microscopy, circular dichroism analysis, dynamic light scattering, rheological analysis, an in vitro release assay, and a cell viability test. Results The results indicated that RADA16 and PTX can interact with each other and that the amphiphilic peptide was able to stabilize hydrophobic drugs in aqueous solution. The particle size of PTX was markedly decreased in the RADA16 solution compared with its size in water. The RADA16-PTX suspension could form a hydrogel in culture medium, and the elasticity of the hydrogel showed a positive correlation with peptide concentration. In vitro release measurements indicated that hydrogels with a higher peptide concentration had a longer half-release time. The RADA16-PTX hydrogel could effectively inhibit the growth of the breast cancer cell line, MDA-MB-435S, in vitro, and hydrogels with higher peptide concentrations were more effective at inhibiting tumor cell proliferation. The RADA16-PTX hydrogel was effective at controlling the release of PTX and inhibiting tumor cell growth in vitro. Conclusion Self-assembling peptide hydrogels may work well as a system for drug delivery.

show abstract

“…These strategies are based on the development of new classes of drugs with unique antibacterial mechanisms or new formulations enabling the reduction of amounts of antimicrobials used worldwide. In particular, investigation of new formulations has been carried out in order to overcome the disadvantages resulting from the administration of antibiotics in conventional forms [5][6][7] .The specific addressing of active molecules to the organ, tissue or cell is considered now as a major challenge and promising route for the treatment of various human diseases, including bacterial infections, cancer or genetic diseases [8] . New carrying and targeting approaches for drug delivery have been extensively studied in recent years.…”

mentioning

confidence: 99%

“…The specific addressing of active molecules to the organ, tissue or cell is considered now as a major challenge and promising route for the treatment of various human diseases, including bacterial infections, cancer or genetic diseases [8] . New carrying and targeting approaches for drug delivery have been extensively studied in recent years.…”

mentioning

confidence: 99%

Preparation and Characterization of Cross-Linked Chitosan Microcapsules for Controlled Delivery of Oxytetracycline

Larbi-Bouamrane¹,

Bal²,

Aliouche³

et al. 2016

pharmaceutical-sciences

View full text Add to dashboard Cite

Larbi-Bouamrane, et al.: Preparation of Chitosan Microcapsules for Delivery of OxytetracyclineFormulations of encapsulated oxytetracycline in chitosan spherical beads have been developed in this work through the ionotropic gelation method in sodium tripolyphosphate or hexametaphosphate and characterized as drug delivery system to the gastrointestinal tract by Fourier transform infrared spectroscopy, thermal analysis and in vitro drug release in simulated gastric fluids. The Fourier transform infrared spectroscopy and differential scanning calorimetry measurements showed that tripolyphosphate and hexametaphosphate are cross-linked ionically to chitosan and there was no significant drug interaction between the entrapped drug and the carrying polymer. With respect to chitosan cross-linking features, sodium hexametaphosphate seems to give better swelling, higher diffusion and faster release kinetics, while addition of glutaraldehyde as a second cross-linking agent lowers the drug discharge. Release extent and kinetics were found to be pH dependent and approximated very well by the multistep models equations of Makoid-Banakar, PeppasSahlin and Korsmeyer-Peppas. Key words: Oxyteracycline, chitosan, encapsulation, crosslinking, release kineticsTetracyclines are broad spectrum antibiotics that exhibit activity against a wide range of Gram-positive and Gram-negative bacteria. Their favourable antimicrobial properties and the absence of major adverse effects have led to their extensive use in the therapy of human and animal infections [1][2][3][4] . Unfortunately, like the other antibiotic and as a result of the extensive prescription in conventional formulations, the emergence of microbial resistance has limited their effectiveness. So, other strategies are needed to keep tetracycline's and other antibiotics as resources for the next generation and to restore their initial antimicrobial activity. These strategies are based on the development of new classes of drugs with unique antibacterial mechanisms or new formulations enabling the reduction of amounts of antimicrobials used worldwide. In particular, investigation of new formulations has been carried out in order to overcome the disadvantages resulting from the administration of antibiotics in conventional forms [5][6][7] .The specific addressing of active molecules to the organ, tissue or cell is considered now as a major challenge and promising route for the treatment of various human diseases, including bacterial infections, cancer or genetic diseases [8] . New carrying and targeting approaches for drug delivery have been extensively studied in recent years. Most of them are centered on the development of nano-or micro-scale carrying systems [9][10][11] or specific molecules to improve and maximize drug bioavailability and hence therapeutic effects over a period of time. This highly selective approach would ensure an optimum response from the dosage form which significantly lowers the side effects and reduce treatment's expense.As non-conventional pharmaceutical dos...

show abstract

Injectable chitosan hydrogels for localised cancer therapy

Cited by 260 publications

References 96 publications

In vivo efficacy of paclitaxel-loaded injectable in situ-forming gel against subcutaneous tumor growth

In vivo efficacy of paclitaxel-loaded injectable in situ-forming gel against subcutaneous tumor growth

Controlled release of paclitaxel from a self-assembling peptide hydrogel formed in situ and antitumor study in vitro

Preparation and Characterization of Cross-Linked Chitosan Microcapsules for Controlled Delivery of Oxytetracycline

Contact Info

Product

Resources

About